Report Detail
Global Bladder Cancer Treatment Drugs Market Insights, Forecast to 2025
- RnM3488022 |
- 04 June, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Bladder cancer refers to the growth of abnormal tissues in the lining of the bladder. These abnormal tissues are referred to as tumor, which even spread in the surrounding tissues or muscles.
The increase in prevalence of bladder cancer, advanced health care services, technological advancements, drug innovations with regard to the treatment of this cancer for ex launch of EOquin, and government initiatives could contribute to the growth of the bladder cancer treatment drugs market. Majority of bladder cancer patients are over the age of 60. Rise in the geriatric population is anticipated to drive the market growth. Additionally, growing awareness about bladder diseases, therapies available in the market, and increasing health care expenditure are significantly contributing toward the growth of the global bladder cancer treatment drugs market. However, rise in number of patent expirations, increase in use of generic drugs, and asymptomatic nature of the disease are some major factors that could hamper the growth of the market.
North America dominates the bladder cancer treatment drugs market followed by Europe. Rise in bladder cancer cases, availability of advanced health care solutions, developed health care infrastructure, and growing concern regarding the disease in these regions are key factors attributed to the significant market share. However, rapidly increasing prevalence of bladder cancer in the Asia Pacific region, in which India being the major country having large number of patients suffering from this disease, is expected to experience a high growth rate in the bladder cancer treatment drugs market over the forecast period. Further, increasing awareness about cancer diagnosis, growing demand for improved bladder cancer treatments and therapies, developing health care infrastructure, and rising health care expenditure in the region can drive the market growth.
The global Bladder Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bladder Cancer Treatment Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Bladder Cancer Treatment Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bladder Cancer Treatment Drugs in these regions.
This research report categorizes the global Bladder Cancer Treatment Drugs market by top players/brands, region, type and end user. This report also studies the global Bladder Cancer Treatment Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
GlaxoSmithKline
Celgene Corporation
Sanofi
Hoffmann-La Roche
Novartis International
Eli Lilly
AstraZeneca
Bristol-Myers Squibb
Market size by Product
Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer
Market size by End User
Low-Grade Tumors
High-Grade Tumors
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Bladder Cancer Treatment Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Bladder Cancer Treatment Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Bladder Cancer Treatment Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Bladder Cancer Treatment Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Bladder Cancer Treatment Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bladder Cancer Treatment Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Bladder Cancer Treatment Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Bladder Cancer Treatment Drugs Market Size Growth Rate by Product
- 1.4.2 Non-Muscle-Invasive Bladder Cancer
- 1.4.3 Muscle-Invasive Bladder Cancer
- 1.5 Market by End User
- 1.5.1 Global Bladder Cancer Treatment Drugs Market Size Growth Rate by End User
- 1.5.2 Low-Grade Tumors
- 1.5.3 High-Grade Tumors
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Bladder Cancer Treatment Drugs Market Size
- 2.1.1 Global Bladder Cancer Treatment Drugs Revenue 2014-2025
- 2.1.2 Global Bladder Cancer Treatment Drugs Sales 2014-2025
- 2.2 Bladder Cancer Treatment Drugs Growth Rate by Regions
- 2.2.1 Global Bladder Cancer Treatment Drugs Sales by Regions
- 2.2.2 Global Bladder Cancer Treatment Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Bladder Cancer Treatment Drugs Sales by Manufacturers
- 3.1.1 Bladder Cancer Treatment Drugs Sales by Manufacturers
- 3.1.2 Bladder Cancer Treatment Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Bladder Cancer Treatment Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Bladder Cancer Treatment Drugs Revenue by Manufacturers
- 3.2.1 Bladder Cancer Treatment Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Bladder Cancer Treatment Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Bladder Cancer Treatment Drugs Price by Manufacturers
- 3.4 Bladder Cancer Treatment Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Bladder Cancer Treatment Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Bladder Cancer Treatment Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Bladder Cancer Treatment Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Bladder Cancer Treatment Drugs Sales by Product
- 4.2 Global Bladder Cancer Treatment Drugs Revenue by Product
- 4.3 Bladder Cancer Treatment Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Bladder Cancer Treatment Drugs Breakdown Data by End User
6 North America
- 6.1 North America Bladder Cancer Treatment Drugs by Countries
- 6.1.1 North America Bladder Cancer Treatment Drugs Sales by Countries
- 6.1.2 North America Bladder Cancer Treatment Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Bladder Cancer Treatment Drugs by Product
- 6.3 North America Bladder Cancer Treatment Drugs by End User
7 Europe
- 7.1 Europe Bladder Cancer Treatment Drugs by Countries
- 7.1.1 Europe Bladder Cancer Treatment Drugs Sales by Countries
- 7.1.2 Europe Bladder Cancer Treatment Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Bladder Cancer Treatment Drugs by Product
- 7.3 Europe Bladder Cancer Treatment Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Bladder Cancer Treatment Drugs by Countries
- 8.1.1 Asia Pacific Bladder Cancer Treatment Drugs Sales by Countries
- 8.1.2 Asia Pacific Bladder Cancer Treatment Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Bladder Cancer Treatment Drugs by Product
- 8.3 Asia Pacific Bladder Cancer Treatment Drugs by End User
9 Central & South America
- 9.1 Central & South America Bladder Cancer Treatment Drugs by Countries
- 9.1.1 Central & South America Bladder Cancer Treatment Drugs Sales by Countries
- 9.1.2 Central & South America Bladder Cancer Treatment Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Bladder Cancer Treatment Drugs by Product
- 9.3 Central & South America Bladder Cancer Treatment Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Bladder Cancer Treatment Drugs by Countries
- 10.1.1 Middle East and Africa Bladder Cancer Treatment Drugs Sales by Countries
- 10.1.2 Middle East and Africa Bladder Cancer Treatment Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Bladder Cancer Treatment Drugs by Product
- 10.3 Middle East and Africa Bladder Cancer Treatment Drugs by End User
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer Bladder Cancer Treatment Drugs Products Offered
- 11.1.5 Pfizer Recent Development
- 11.2 GlaxoSmithKline
- 11.2.1 GlaxoSmithKline Company Details
- 11.2.2 Company Business Overview
- 11.2.3 GlaxoSmithKline Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 GlaxoSmithKline Bladder Cancer Treatment Drugs Products Offered
- 11.2.5 GlaxoSmithKline Recent Development
- 11.3 Celgene Corporation
- 11.3.1 Celgene Corporation Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Celgene Corporation Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Celgene Corporation Bladder Cancer Treatment Drugs Products Offered
- 11.3.5 Celgene Corporation Recent Development
- 11.4 Sanofi
- 11.4.1 Sanofi Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Sanofi Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Sanofi Bladder Cancer Treatment Drugs Products Offered
- 11.4.5 Sanofi Recent Development
- 11.5 Hoffmann-La Roche
- 11.5.1 Hoffmann-La Roche Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Hoffmann-La Roche Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Hoffmann-La Roche Bladder Cancer Treatment Drugs Products Offered
- 11.5.5 Hoffmann-La Roche Recent Development
- 11.6 Novartis International
- 11.6.1 Novartis International Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Novartis International Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Novartis International Bladder Cancer Treatment Drugs Products Offered
- 11.6.5 Novartis International Recent Development
- 11.7 Eli Lilly
- 11.7.1 Eli Lilly Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Eli Lilly Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Eli Lilly Bladder Cancer Treatment Drugs Products Offered
- 11.7.5 Eli Lilly Recent Development
- 11.8 AstraZeneca
- 11.8.1 AstraZeneca Company Details
- 11.8.2 Company Business Overview
- 11.8.3 AstraZeneca Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 AstraZeneca Bladder Cancer Treatment Drugs Products Offered
- 11.8.5 AstraZeneca Recent Development
- 11.9 Bristol-Myers Squibb
- 11.9.1 Bristol-Myers Squibb Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Bristol-Myers Squibb Bladder Cancer Treatment Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Bristol-Myers Squibb Bladder Cancer Treatment Drugs Products Offered
- 11.9.5 Bristol-Myers Squibb Recent Development
12 Future Forecast
- 12.1 Bladder Cancer Treatment Drugs Market Forecast by Regions
- 12.1.1 Global Bladder Cancer Treatment Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Bladder Cancer Treatment Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Bladder Cancer Treatment Drugs Market Forecast by Product
- 12.2.1 Global Bladder Cancer Treatment Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Bladder Cancer Treatment Drugs Revenue Forecast by Product 2019-2025
- 12.3 Bladder Cancer Treatment Drugs Market Forecast by End User
- 12.4 North America Bladder Cancer Treatment Drugs Forecast
- 12.5 Europe Bladder Cancer Treatment Drugs Forecast
- 12.6 Asia Pacific Bladder Cancer Treatment Drugs Forecast
- 12.7 Central & South America Bladder Cancer Treatment Drugs Forecast
- 12.8 Middle East and Africa Bladder Cancer Treatment Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Bladder Cancer Treatment Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Bladder Cancer Treatment Drugs . Industry analysis & Market Report on Bladder Cancer Treatment Drugs is a syndicated market report, published as Global Bladder Cancer Treatment Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Bladder Cancer Treatment Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
